Ginkgo bioworks reports second quarter 2023 financial results

Ginkgo added 21 new cell programs to the foundry platform in q2 2023 highlighted continued success selling into large established biotech r&d organizations with recently expanded relationships with sumitomo, novo nordisk, and merck ginkgo ended q2 2023 with approximately $1.1 billion in cash and cash equivalents, providing a strong multi-year runway as ginkgo continues to drive towards profitability boston , aug. 9, 2023 /prnewswire/ -- ginkgo bioworks holdings, inc. (nyse: dna, "ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended june 30, 2023. the update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.
DNA Ratings Summary
DNA Quant Ranking